---
reference_id: "PMID:37655226"
title: Impact of the updated chronic inflammatory demyelinating polyneuropathy guideline on everyday clinical practice.
authors:
- Muley S
- Beydoun SR
journal: Ther Adv Neurol Disord
year: '2023'
doi: 10.1177/17562864231190549
content_type: abstract_only
---

# Impact of the updated chronic inflammatory demyelinating polyneuropathy guideline on everyday clinical practice.
**Authors:** Muley S, Beydoun SR
**Journal:** Ther Adv Neurol Disord (2023)
**DOI:** [10.1177/17562864231190549](https://doi.org/10.1177/17562864231190549)

## Content

1. Ther Adv Neurol Disord. 2023 Aug 24;16:17562864231190549. doi: 
10.1177/17562864231190549. eCollection 2023.

Impact of the updated chronic inflammatory demyelinating polyneuropathy 
guideline on everyday clinical practice.

Muley S(1), Beydoun SR(2).

Author information:
(1)Bob Bove Neuroscience Institute at HonorHealth, 7242 E. Osborn Rd, 
Scottsdale, AZ 85251, USA.
(2)Neuromuscular Division, Department of Neurology, University of Southern 
California, Los Angeles, CA, USA.

DOI: 10.1177/17562864231190549
PMCID: PMC10467171
PMID: 37655226

Conflict of interest statement: Dr Beydoun received research grants from AB 
Science, Alexion, Amylyx, Argenx, Genentech, Healey ALS Center—Massachusetts 
General Hospital, Janssen, Regeneron, Sanofi, and UCB Pharma; honoraria for 
consulting or speaking from Alexion, Alnylam, Argenx, CSL Behring, Grifols, 
Pfizer, and Takeda. Dr Muley received consulting fees from Takeda, Alexion, UCB, 
Horizon, and Argenx; honoraria for consulting or speaking for CSL Behring, 
Takeda, Argenx, Alexion, and Catalyst; royalties or licenses for UpToDate® 
articles (“Chronic inflammatory demyelinating polyneuropathy: etiology, clinical 
features, and diagnosis,” “Chronic inflammatory demyelinating polyneuropathy: 
treatment and prognosis,” and “Guillain–Barré syndrome in adults: treatment and 
prognosis”).